IP Library › Granted Patent US 7,572,596
Granted Patent B2
US 7,572,596 · App. 11/294,161 · Granted Aug 11, 2009

Modulation of the neuroendoctrine system as a therapy for motor neuron disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,572,596
App. No.
11/294,161
Granted
Aug 11, 2009
Kind
B2
Abstract

The invention provides a method for treating amyotrophic lateral sclerosis (ALS) in a subject. The method comprises administering to the nervous system of the subject a composition comprising a thyroxine protein or a therapeutic fragment or pharmacologic mimic thereof and a pharmaceutically acceptable carrier. The invention also provides a method for treating ALS in a subject that comprises administering to the subject a transthyretin protein, 7B2 protein, a cystatin C protein, a neuroendocrine protein, a cysteine protease inhibitor, or an inhibitor of an enzyme that processes a 7B2 protein. In addition, the invention provides methods for determining the susceptibility of a subject to developing ALS and for determining the progression of ALS in a subject.

Claims (12)

1. A method comprising

(a) obtaining a fluid sample selected from the group consisting of cerebrospinal fluid, blood serum, plasma, and urine from an individual at risk of or who has been diagnosed with amyotrophic lateral sclerosis (ALS), (b) analyzing the cystatin C protein levels from the sample, and (c) comparing the cystatin C protein levels to a control sample wherein cystatin C protein levels of the sample that are lower than cystatin C protein levels of the control sample is indicative of ALS.

2. The method of claim 1 , wherein the level of cystatin C protein is indicative of the progression of ALS.

3. The method of claim 1 , wherein the samples are analyzed by mass spectroscopy.

4. The method of claim 1 , wherein the samples are analyzed using immunological techniques.

5. The method of claim 1 , wherein the samples are analyzed by ELISA.

6. The method of claim 1 , wherein the samples are analyzed by immunoblot.

7. The method of claim 1 , wherein the individual is a human.

8. The method of claim 1 wherein the level of protein is compared to a normal control from an individual without ALS.

9. The method of claim 1 wherein the level of protein is compared to a control from an individual with ALS.

10. The method of claim 1 wherein the level of protein is correlated with the progression of ALS in an individual previously diagnosed with ALS.

11. The method of claim 10 wherein the individual is being treated to alleviate one or more symptoms of ALS.